Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

Leukemia

Volumn 26, Issue 8, 2012, Pages 1895-1898

  Royo, C ^a   Navarro, A ^a   Clot, G ^a   Salaverria, I ^a,b   Gine E ^c   Jares, P ^a   Colomer, D ^a   Wiestner, A ^d   Wilson, W H ^d   Vegliante, M C ^a   Fernandez, V ^a   Hartmann, E M ^e   Trim, N ^f   Erber, W N ^g   Swerdlow, S H ^h   Klapper, W ^b   Dyer, M J S ⁱ   Vargas Pabon M ^j   Ott, G ^k   Rosenwald, A ^e   Siebert, R ^b   Lopez Guillermo A ^c   Campo, E ^a   Bea S ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF KIEL   (Germany)

^c HOSPITAL CLÍNIC   (Spain)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j Hospital de Jarrio   (Spain)

^k ROBERT BOSCH GMBH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE;

CANCER CHEMOTHERAPY; CLINICAL FEATURE; GENE EXPRESSION; HUMAN; LETTER; LYMPHADENOPATHY; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE; TUMOR GENE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84864877555     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.72     Document Type: Letter

References (15)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
2. Royo C, Salaverria I, Hartmann E, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011; 5: 322-334.
3. Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 27; 2009: e189-e190.
4. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
5. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
6. Ondrejka SL, Lai R, Kumar N, Smith SD, Hsi ED. Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011; 96: 1121-1127.
7. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975-4981.
8. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
9. Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann EM et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-3069.
10. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116: 953-961.
11. Martin P, Leonard J. Is there a role for "watch and wait" in patients with mantle cell lymphoma? Semin Hematol 2011; 48: 189-193.
12. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135-141.
13. Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009; 23: 212-214.
14. Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP, Kontopidou FN, Rassidakis GZ, Dimopoulou MN et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002; 68: 12-21.
15. Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97: 270-278.